Aspirin or Rivaroxaban for Preventing Venous Thromboembolism after Total Knee Arthroplasty .
Aspirin versus Rivaroxaban to Prevent Venous Thromboembolism after Total Knee Arthroplasty: A Double-blinded, Randomized Controlled Trial
Rev Bras Ortop (Sao Paulo) . 2021 Oct 25;57(5):741-746Forty patients undergoing total knee arthroplasty for primary knee osteoarthritis were randomized to receive either rivaroxaban (n=20) or Aspirin (acetylsalicylic acid; n=20). Outcomes of interest were hematocrit levels, deep vein thrombosis, and adverse events. Hematocrit levels at 6 and 24 hours, and 2 weeks were similar between the two groups. The incidence of blood transfusion, bleeding, wound complications, and reoperations were also similar between the two groups. No patients presented with deep vein thrombosis or pulmonary embolism.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
